Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026
Same author

ALS-FTD-linked CCNF<sup>S621G</sup> drives increased hippocampal astrocyte ramification and mitochondrial dysfunction and impairs motor neuron excitability.

Journal of neuroinflammation·2026
Same author

Genetic risk for schizophrenia modulates WIN 55,212-2 reward: Evidence from a heterozygous transmembrane domain neuregulin 1 mutant mouse model.

Psychopharmacology·2026
Same author

Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio - a new therapeutic strategy for APP<sub>Swe</sub>/PS1ΔE9 transgenic mice?

Neurobiology of aging·2026
Same author

Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic <i>APP<sub>Swe</sub>/PS1∆E9</i> Mice.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

NF-κB pathway gene expression is elevated in the midbrain of people with high-inflammation schizophrenia.

Brain, behavior, and immunity·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Carla Lucia Wahlich1, Tim Karl2

  • 1Friedrich-Alexander-University, Erlangen, Bavaria, Germany.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

这项研究研究了大麻 (CBD) 和delta-9-tetrahydrocannabinol (THC) 对阿尔茨海默病 (AD) 鼠标模型的影响. 长期的CBD:THC治疗对与陶病相关的行为产生了微妙的治疗益处,这表明AD多种大麻素治疗的潜力.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 遗传学 遗传学 是一个

背景情况:

  • 阿尔茨海默病 (AD) 疗法取得的成功有限,需要替代疗法.
  • 类大麻素,如大麻 (CBD) 和delta-9-tetrahydrocannabinol (THC),具有抗炎性质,并且耐受性很好.
  • 对于CBD和THC在阿尔茨海默病的关键特征tau病理上的联合作用,人们对其了解甚少.

研究的目的:

  • 评估慢性CBD和THC联合治疗对雌性TAU58/2转基因小鼠疾病相关行为的影响.
  • 在AD小鼠模型中研究特定CBD:THC比率 (50:3 mg/kg/天) 的治疗潜力.
  • 探索大麻素对运动功能,记忆,焦虑和感觉运动门的影响,在病的背景下.

主要方法:

  • 六个月大的雌性TAU58/2转基因小鼠和野生型对照被用CBD+THC (50:3 mg/kg/天) 或载体治疗了五周.
  • 在治疗三周后进行了行为评估,包括运动功能,空间和社会识别记忆,焦虑和感觉运动门.
  • 数据分析的重点是治疗和基因型对各种行为测试的影响.

主要成果:

  • TAU58/2小鼠在运动功能,感觉运动门,焦虑类行为和空间记忆方面表现出缺陷.
  • 慢性CBD:THC联合治疗显著改善了转基因小鼠的运动功能,并部分减少了类似焦虑的行为.
  • 大麻素显示出改善空间记忆的趋势,尽管在统计学上并不显著;社会识别和感觉运动门不受影响.

结论:

  • 长期的CBD:THC治疗 (50:3毫克/公斤/天) 对中年老鼠的病相关行为表现出微妙但有前途的治疗效果.
  • 这项研究提供了第一个证据,证明CBD:THC联合治疗在解决病的行为症状方面的治疗潜力.
  • 研究结果表明,多种大麻素疗法,特别是特定的比率,可能对阿尔茨海默病的治疗有前途,这需要进一步研究潜在的分子机制.